Skip to main content

JOHNSON & JOHNSON

corporate_fare Company Profile

JOHNSON & JOHNSON

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Exchange: NYSESector: Life Sciences

show_chartPrice Chart

Loading chart...

feed JNJ - Latest Insights

JNJ
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
JNJ
Apr 24, 2026, 9:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
JNJ
Apr 22, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
JNJ
Apr 22, 2026, 10:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
JNJ
Apr 17, 2026, 6:47 PM EDT
Source: Reuters
Importance Score:
8
JNJ
Apr 14, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
JNJ
Apr 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
JNJ
Apr 14, 2026, 6:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
JNJ
Apr 13, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
JNJ
Mar 30, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
JNJ
Mar 28, 2026, 10:03 AM EDT
Source: Reuters
Importance Score:
7
JNJ
Mar 27, 2026, 3:04 PM EDT
Source: Reuters
Importance Score:
8
JNJ
Mar 09, 2026, 1:07 PM EDT
Source: Reuters
Importance Score:
8
JNJ
Mar 06, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
8
JNJ
Mar 03, 2026, 8:11 AM EST
Source: Reuters
Importance Score:
7
JNJ
Feb 11, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
JNJ
Jan 21, 2026, 7:46 AM EST
Filing Type: 8-K
Importance Score:
7